Search Results

within the urologic community that the 9% increase in disease-specific survival is of small magnitude. 24 Adjuvant Chemotherapy The NCCN Guidelines confer a category 2B recommendation (lower-level of evidence and consensus) for use of adjuvant

in cancer care, from both academic and community perspectives. We are particularly seeking original research and insightful commentary on the best ways to use resources and improve outcomes for patients. Examples of such contributions might include

, creating dedicated patient care facilities, and educating the community about AYA oncology. Program development during the first 2 years addressed the most glaring unmet needs of AYAs treated in a pediatric hospital. Institutional approval was obtained to

in a community health system is feasible and associated with multiple benefits. Increased navigator patient volumes and navigator productivity were observed. Navigator time spent with patients and physicians increased with a concurrent reduction in

satisfaction data will be disseminated. Conclusion: The oncology community is eager to provide patients with scalp cooling, but no literature to date has described the management aspects of implementation. This presentation will offer comprehensive

community focus on cancer care, it is critical that the oncology community be actively involved in the development and implementation of processes at all levels. To address the knowledge gap problem with CER, consideration must be given to the current

of psychologists, social workers, nurses, counselors, and psychiatrists, it has maintained a helpline (1-866-276-7443) since 2003 to help patients find a counselor in their local community through a directory maintained by the society. This can serve

therapeutic developments. Nonetheless, significant controversies remain, and these controversies can cause major disagreement among experts. This issue of JNCCN proves this point and also illustrates the importance that we in the medical community must place

disease response or tumor type: results from a prospective community oncology study. Procrit Study Group . J Clin Oncol 1998 ; 16 : 3412 – 3425 . 10 Gabrilove JL Cleeland CS Livingston RB . Clinical evaluation of once-weekly dosing of

–agnostic approvals that were based on common genetic alterations rather than the tissue of origin. The OCE coordinated work across the various medical product centers throughout the FDA, and with the cancer research community, to make these advancements possible